FDA Declares Zepbound No Longer in Shortage: A Legal Perspective on the Implications for Patients, Pharmacies, and the Industry
On December 19, 2024, the U.S. Food and Drug Administration (FDA) made a critical ruling that has major legal and regulatory consequences for the healthcare sector. The FDA declared that the shortage of tirzepatide, the active ingredient in Eli Lilly’s weight loss...
Breaking News: FDA Reevaluates Tirzepatide Drug Shortage: A Win for the Aesthetics Industry and Compounding Pharmacies
The U.S. District Court for the Northern District of Texas recently released a joint status report in the case Outsourcing Facilities Association v. U.S. Food and Drug Administration (Case No. 4:24-cv-00953-P). This report, filed on November 21, 2024, outlines ongoing...
Countdown to November 21: What the FDA’s Tirzepatide Decision Means for Medical Spas
The FDA’s recent decision to remove tirzepatide from its shortage list has triggered a legal battle with significant implications for medical spas and compounders. In response to a lawsuit filed by the Outsourcing Facilities Association (OFA) and North American Custom...
Massachusetts Spa Owner Arrested for Allegedly Conducting Thousands of Illegal Injections Using Counterfeit Products: A Reminder of the Importance of Safety and Compliance in the Med Spa Industry
The recent case involving Rebecca Fadanelli, owner of Skin Beaute Med Spa, who was arrested on November 1, 2024, on charges of illegal medical practices, is a stark reminder of the importance of integrity and compliance within the med spa industry. While this...